227 related articles for article (PubMed ID: 36653153)
1. The molecular biology of thyrotroph pituitary neuroendocrine tumors.
Horiguchi K
Endocr J; 2023 Feb; 70(2):135-139. PubMed ID: 36653153
[TBL] [Abstract][Full Text] [Related]
2. Progress in the Pathogenesis, Diagnosis, and Treatment of TSH-Secreting Pituitary Neuroendocrine Tumor.
Luo P; Zhang L; Yang L; An Z; Tan H
Front Endocrinol (Lausanne); 2020; 11():580264. PubMed ID: 33329389
[TBL] [Abstract][Full Text] [Related]
3. Clinical Characteristics, Diagnosis, and Treatment of Thyroid Stimulating Hormone-Secreting Pituitary Neuroendocrine Tumor (TSH PitNET): A Single-Center Experience.
Heo J; Suh YL; Kim SH; Kong DS; Nam DH; Lee WJ; Kim ST; Hong SD; Ryu S; Lee YB; Kim G; Jin SM; Kim JH; Hur KY
Endocrinol Metab (Seoul); 2024 Apr; 39(2):387-396. PubMed ID: 38311828
[TBL] [Abstract][Full Text] [Related]
4. Overview of the 2022 WHO Classification of Pituitary Tumors.
Asa SL; Mete O; Perry A; Osamura RY
Endocr Pathol; 2022 Mar; 33(1):6-26. PubMed ID: 35291028
[TBL] [Abstract][Full Text] [Related]
5. Pituitary Gangliocytoma Producing TSH and TRH: A Review of "Gangliocytomas of the Sellar Region".
Sakata K; Fujimori K; Komaki S; Furuta T; Sugita Y; Ashida K; Nomura M; Morioka M
J Clin Endocrinol Metab; 2020 Oct; 105(10):3109-21. PubMed ID: 32706866
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptor profile in pituitary thyrotroph adenomas.
Thodou E; Kontogeorgos G
Clin Neurol Neurosurg; 2020 Aug; 195():105865. PubMed ID: 32416325
[TBL] [Abstract][Full Text] [Related]
7. A review of multiomics platforms in pituitary adenoma pathogenesis.
Mouchtouris N; Smit RD; Piper K; Prashant G; Evans JJ; Karsy M
Front Biosci (Landmark Ed); 2022 Mar; 27(3):77. PubMed ID: 35345309
[TBL] [Abstract][Full Text] [Related]
8. Unveiling the identities of null cell tumours: Epigenomics corroborate subtle histological cues in pituitary neuroendocrine tumour/adenoma classification.
Dottermusch M; Schüller U; Hagel C; Saeger W
Neuropathol Appl Neurobiol; 2023 Feb; 49(1):e12870. PubMed ID: 36527335
[TBL] [Abstract][Full Text] [Related]
9. Expression of kisspeptin and KISS1 receptor in pituitary neuroendocrine tumours - an immunohistochemical study.
Mihajlovic M; Pekic S; Doknic M; Stojanovic M; Miljic D; Soldatovic I; Vukotic T; Janev T; Cirovic S; Terzic T; Raicevic S; Skender-Gazibara M; Popovic V; Manojlovic-Gacic E
Endokrynol Pol; 2021; 72(2):91-96. PubMed ID: 33619706
[TBL] [Abstract][Full Text] [Related]
10. Clinical presentation and recurrence of pituitary neuroendocrine tumors: results from a single referral center in Colombia.
Jimenez-Canizales CE; Rojas W; Alonso D; Romero I; Tabares S; Veronesi Zuluaga LA; Modica R; Colao A
J Endocrinol Invest; 2023 Nov; 46(11):2275-2286. PubMed ID: 37002436
[TBL] [Abstract][Full Text] [Related]
11. [TSH-secreting pituitary tumors: two case reports and literature review].
Duarte FH; Jallad RS; Salgado LR; Bronstein MD
Arq Bras Endocrinol Metabol; 2009 Dec; 53(9):1157-66. PubMed ID: 20126874
[TBL] [Abstract][Full Text] [Related]
12. Refractory Pit1 plurihormonal tumours and thyrotroph adenomas.
Nf L; Ai M
Pituitary; 2023 Apr; 26(2):182-186. PubMed ID: 37117845
[TBL] [Abstract][Full Text] [Related]
13. Co-occurrence of Pituitary Neuroendocrine Tumors (PitNETs) and Tumors of the Neurohypophysis.
Saeger W; von Schöning J; Flitsch J; Jautzke G; Bergmann M; Hagel C; Knappe UJ
Endocr Pathol; 2021 Dec; 32(4):473-479. PubMed ID: 34129177
[TBL] [Abstract][Full Text] [Related]
14. Differential expression levels of β-catenin are associated with invasive behavior of both functional and non-functional pituitary neuroendocrine tumor (PitNET).
Taghavi SF; Ghorbani M; Panahi M; Nazem S; Karimi M; Salimi V; Tavakoli-Yaraki M
Mol Biol Rep; 2023 Aug; 50(8):6425-6434. PubMed ID: 37326745
[TBL] [Abstract][Full Text] [Related]
15. Imaging of pituitary tumors: an update with the 5th WHO Classifications-part 1. Pituitary neuroendocrine tumor (PitNET)/pituitary adenoma.
Tsukamoto T; Miki Y
Jpn J Radiol; 2023 Aug; 41(8):789-806. PubMed ID: 36826759
[TBL] [Abstract][Full Text] [Related]
16. Multiple tumorous lesions of the pituitary gland.
Schöning JV; Flitsch J; Lüdecke DK; Fahlbusch R; Buchfelder M; Buslei R; Knappe UJ; Bergmann M; Schulz-Schaeffer WJ; Herms J; Glatzel M; Saeger W
Hormones (Athens); 2022 Dec; 21(4):653-663. PubMed ID: 35947342
[TBL] [Abstract][Full Text] [Related]
17. Pleiomorphism plurihormonal Pit-1-positive macroadenoma with central hyperthyroidism: a rare case report and literature review.
Peng G; Guo C; Lv Y; Li D; Zhou L; Shen R; Chen Y; Zheng X; Sun Z; Zheng H; Long M
BMC Endocr Disord; 2022 Dec; 22(1):325. PubMed ID: 36539773
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress in pituitary neuroendocrine tumors: Affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy.
Zhou Y; Zhang A; Fang C; Yuan L; Shao A; Xu Y; Zhou D
CNS Neurosci Ther; 2023 Oct; 29(10):2744-2759. PubMed ID: 37341156
[TBL] [Abstract][Full Text] [Related]
19. Two Pituitary Neuroendocrine Tumors (PitNETs) with Very High Proliferation and TP53 Mutation - High-Grade PitNET or PitNEC?
Saeger W; Mawrin C; Meinhardt M; Wefers AK; Jacobsen F
Endocr Pathol; 2022 Jun; 33(2):257-262. PubMed ID: 34669159
[TBL] [Abstract][Full Text] [Related]
20. Thyrotropin-secreting tumor "TSH-PitNET": From diagnosis to treatment.
Briet C; Suteau V; Illouz F; Rodien P
Ann Endocrinol (Paris); 2023 Aug; 84(4):407-412. PubMed ID: 36716819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
